Antibacterial therapy of infectious exacerbation of chronic obstructive pulmonary disease: patients with risk of poor response to the antibacterial agents


Cite item

Full Text

Abstract

Among patients with infectious exacerbation of chronic obstructive pulmonary disease (COPD) approximately 10 to 20 % of patients have poor response to antibacterial therapy (ABT). The main risk factors of poor response to the ABT patients with infectious exacerbation of COPD are elderly and senile age, marked bronchial obstruction, comorbidity, low treatment compliance, antibiotic resistance, and side effects of ABT. For the management of patients with infectious exacerbation of COPD, the attending physician must take into account all predictors of poor response to ABT for the purpose of selection an adequate antibacterial agent and a possible correction of therapy in case of ineffectiveness in this group of patients.

References

  1. Miravitlles М. Exacerbations of chronic оbstructive pulmonary disease when are bacteria important? Eur Respir J 2002;20(Suppl. 36):9-19.
  2. Beghi G, Berni F, Carratu L, et al. Efficacy and tolerability of azithromycin versus amoxicillin|clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 1995;7:146-52.
  3. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Антибактериальная терапия обострений хронического бронхита. Результаты длительного мониторинга больных // Терапевтический архив. 2006. № 3.
  4. Siempos I, Dimopoulos G, Korbila I, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007;29:1127-37.
  5. Miravitlles M. Grupo de trabajo de la Asociacion Latinoamericana del Torax (ALAT). Update to the Latin American Thoracic Association (ALAT) Recommendations on Infectious Exacerbation of Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2004;40:315-25.
  6. Чучалин А. Г., Синопальников А. И., Козлов Р. С. и др. Инфекционнное обострение хронической обструктивной болезни легких (Практические рекомендации по диагностике, лечению и профилактике) // Российский медицинский вестник. 2006. № 12. С. 4-18.
  7. Albertson ТE, Chan AL. Antibiotic Therapy in Elderly Patients with Acute Exacerbation of Chronic Bronchitis. Expert Rev Resp Med 2009;3(5):539-48.
  8. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis relations bettween bacteriologic etiology and lung function. Chest 1998;113(6):1542-48.
  9. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II // Клиническая микробиология и антимикробная химиотерапия. 2006. № 8 (1). С. 33-47.
  10. Филимонова О.Ю., Грудинина С.А., Сидоренко С.В. и др. Антибиотикорезистентность штаммов Haemophilus influenzae, выделенных в Москве с 2002 по 2004 гг. // Антибиотики и химиотерапия. 2004. № 49. С. 14-20.
  11. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46.
  12. Авдеев С.Н., Шанина А.Г., Чучалин А.Г. Бактериальная инфекция у больных ХОБЛ с острой дыхательной недостаточностью // Клиническая микробиология и антимикробная химиотерапия. 2005. № 7. С. 245-254.
  13. Esel D, Ay-Altintop Y, Yagmur G, et al. Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis. Clin Microbiol Infect 2007;13:1023-25.
  14. Beekmann SE, Heilmann KP, Richter SS, et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 2005;25:148-56.
  15. Pankuch GA, Jueneman SA, Davies TA, et al. In vitro selection of resistance to four beta-lactams and azitromycin in S. pneumoniae. Antimicrob Agents Chemother 1998;42:2914-18.
  16. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
  17. Bont J, Hak E, Birkhoff CE, et al. Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations? Family Practice 2007;1-6).
  18. Pechere J, Hughes D, Kardas P, et al. Non compliance with antibiotic therapy for acute community infections: a global survey. Int J of Antimicrob Agents 2007;29:245-53.
  19. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Аntimicrob Сhemother 2007;59(3):531-36.
  20. Niederman MS. What are the benefits of antibiotics in acute exacerbations of COPD? 13th ERS Annual Congress, Vienna, 2003 personal communicftion).
  21. WHO Model Prescribing Information, Drugs used in bacterial infections. WHO, Geneva, Switzerland, 2001.
  22. Neu HC, Wilson AP, Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993;5:67-93.
  23. Garau J, Twynholm M, Garcia-Mendez E, et al. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003;52:826-36.
  24. Henry DC, Riffer E, Sokol WN, et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003;47:2770-74.
  25. File TM Jr., Lode H, Kurz H, et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother 2004;48:3323-31.
  26. Wistrom J, Norrby SR, Myhre EB. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47(1):43-50.
  27. Sourgens H, Steinbrede H, Verschoor JS, et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator filmcoated tablet. Int J Clin Pharmacol Ther 2001;39:75-82.
  28. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина/клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование // Пульмонология. 2008. № 2. С. 73-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies